Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifaximin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 2/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifaximin SCHEMBL16351426 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124066 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL16229249 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL874028 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL14677545 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL13897021 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL23314507 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL9397878 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL17930616 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124067 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2506 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034091-B1 | RIFAXIMIN LIQUID FORMULATIONS | BAUSCH HEALTH IRELAND LTD (IE) | 2026-05-20 | — | — | EP | claimed |
| EP-3586131-B1 | MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4137132-B1 | SOLID DISPERSION FORMS OF RIFAXIMIN | SALIX PHARMACEUTICALS INC (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-3600303-B1 | A COMPOSITION COMPRISING A RIFAXIMIN AND A COMBINATION OF A VANCOMYCIN, A METRONIDAZOLE, AND/OR A TINIDAZOLE FOR TREATING AUTISM | BORODY THOMAS J (AU) | 2025-07-23 | — | — | EP | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2007065167-A1 | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-06-07 | — | — | WO | claimed |
| EP-1557421-B1 | Polymorphous form of rifaximin as antibiotic | ALFA WASSERMANN SPA (IT) | 2007-05-09 | — | — | EP | claimed |
| CN-1272072-C | Triple combination of Planick-cholate phosphate in use for carrier of hard-soluble medication | JOANGSU UNIV (CN) | 2006-08-30 | — | — | CN | claimed |
| CN-1683015-A | Polyvidone-phospholipid-cholate ternary composition used for difficult soluble medicine carrier | UNIV JIANGSU (CN) | 2005-10-19 | — | — | CN | claimed |
| CN-1660440-A | Triple combination of Planick-cholate phosphate in use for carrier of hard-soluble medication | JOANGSU UNIV (CN) | 2005-08-31 | — | — | CN | claimed |
| EP-0858804-B1 | Use of rifaximin as medicament for the treatment of the diarrhoea from cryptosporidiosis | ALFA WASSERMANN SPA (IT) | 2002-06-05 | — | — | EP | claimed |
| EP-0616808-B1 | Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori | ALFA WASSERMANN SPA (IT) | 1996-09-11 | — | — | EP | claimed |
| EP-0547294-B1 | Pharmaceutical compositions containing rifaximin for treatment of vaginal infections | ALFA WASSERMANN SPA (IT) | 1995-11-22 | — | — | EP | claimed |
| EP-0222712-B1 | VETERINARY COMPOSITIONS CONTAINING ANTIMICROBIAL AGENTS, AND THEIR USE | FATRO S.p.A: (IT) | 1990-06-06 | — | — | EP | claimed |
| EP-0222712-A2 | Veterinary compositions containing antimicrobial agents, and their use | FATRO S.p.A: (IT) | 1987-05-20 | — | — | EP | claimed |